{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:43:49Z","timestamp":1789145029155,"version":"build-2803163510"},"reference-count":53,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1080\/21645515.2023.2228162","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T11:11:32Z","timestamp":1688123492000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study"],"prefix":"10.1080","volume":"19","author":[{"given":"Miwa","family":"Haranaka","sequence":"first","affiliation":[{"name":"SOUSEIKAI PS Clinic","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yono","sequence":"additional","affiliation":[{"name":"Nishi-Kumamoto Hospital","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kishino","sequence":"additional","affiliation":[{"name":"MSD K.K","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Igarashi","sequence":"additional","affiliation":[{"name":"MSD K.K","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Oshima","sequence":"additional","affiliation":[{"name":"MSD K.K","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Sawata","sequence":"additional","affiliation":[{"name":"MSD K.K","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather Loryn","family":"Platt","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31012-1"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.017"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-2113-y"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122247"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz743"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28962"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1690332"},{"key":"e_1_3_6_9_1","first-page":"107","article-title":"Pneumococcal infections in 2017, Japan","volume":"39","author":"National Institute for Infectious Diseases","year":"2018","unstructured":"National Institute for Infectious Diseases. Pneumococcal infections in 2017, Japan. IASR. 2018;39:107\u20138.","journal-title":"IASR"},{"key":"e_1_3_6_10_1","unstructured":"PMDA: Pharmaceuticals and Medical Devices Agency. PPSV23 product information - Japan. 2022 [accessed Apr 21]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/170050_6311400G1021_1_03."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169368"},{"key":"e_1_3_6_12_1","unstructured":"PMDA: Pharmaceuticals and Medical Devices Agency. Prevenar 13 suspension liquid for injection - product information. 2021 [accessed Apr 21]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/672212_631140EC1022_2_04."},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2610.191531"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06950-w"},{"key":"e_1_3_6_15_1","unstructured":"Japan Pediatric Society. Changes in the immunization schedule recommended by the Japan Pediatric Society. 2020 [accessed Oct 7]. https:\/\/www.jpeds.or.jp\/uploads\/files\/2020%20English%20JPS%20Immunization%20Schedule.pdf."},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.005"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.06.018"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy872"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1277300"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2020.44.40"},{"key":"e_1_3_6_21_1","unstructured":"National institute of infectious diseases and tuberculosis and infectious diseases control division ministry of health labour and welfare. Infectious Agents Surveillance Report 2018."},{"key":"e_1_3_6_22_1","unstructured":"Food and Drug Administration. VAXNEUVANCE\u2122 (Pneumococcal 15-valent conjugate vaccine) prescribing information. 2021. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaxneuvance."},{"key":"e_1_3_6_23_1","unstructured":"European Medicines Agency. Vaxneuvance Summary of Product Characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxneuvance-epar-product-information_en.pdf."},{"key":"e_1_3_6_24_1","unstructured":"Government of Canada. VAXNEUVANCE pneumococcal 15-valent conjugate vaccine CRM. 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00066824.PDF."},{"key":"e_1_3_6_25_1","unstructured":"Food and Drug Administration. Prevnar 20 Package insert. 2021. https:\/\/www.fda.gov\/media\/149987\/download."},{"key":"e_1_3_6_26_1","unstructured":"Pfizer. Prevnar 20 summary of product characteristics. 2021 Jun 21 https:\/\/www.fda.gov\/media\/1499871\/download."},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0651-y"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00526-6"},{"key":"e_1_3_6_29_1","unstructured":"Batah J Varon E. National pension fund and social security fund activity report 2018 (Epidemiology 2017). France-National Reference Center Pneumococci; 2018. 1\u201389."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220453"},{"key":"e_1_3_6_31_1","unstructured":"Government of Canada. National laboratory surveillance of invasive streptococcal disease in Canada - Annual summary 2018. 2018. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/drugs-health-products\/national-laboratory-surveillance-invasive-streptococcal-disease-canada-annual-summary-2018.html."},{"key":"e_1_3_6_32_1","unstructured":"Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs). Trends by serotype group. 2018. https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu-types.html."},{"key":"e_1_3_6_33_1","unstructured":"UK Health Security Agency. Pneumococcal disease infections caused by serotypes not in Prevenar 13 vaccine. 2022. https:\/\/www.gov.uk\/government\/publications\/pneumococcal-disease-caused-by-strains-not-covered-by-prevenar-13-vaccine\/pneumococcal-disease-infections-caused-by-serotypes-not-in-prevenar-13-vaccine."},{"key":"e_1_3_6_34_1","unstructured":"UK Health Security Agency. Pneumococcal disease infections caused by serotypes in Prevenar 13 and not in Prevenar 7. 2022. https:\/\/www.gov.uk\/government\/publications\/pneumococcal-disease-caused-by-strains-in-prevenar-13-and-not-in-prevenar-17-vaccine\/pneumococcal-disease-infections-caused-by-serotypes-in-prevenar-13-and-not-in-prevenar-7."},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00099-17"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1985353"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.08.027"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75691-5"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080814"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa917"},{"key":"e_1_3_6_41_1","first-page":"585","volume-title":"12th International Symposium on Pneumococci and Pneumococcal Diseases","author":"Skinner J","year":"2022","unstructured":"Skinner J, McGuinness D, Briggs ML, Curry S, He J, Joyce JG, Kaufhold RM, Kim E, McHugh P, Monslow M, et al. Preclinical immunogenicity of V116, a pneumococcal conjugate vaccine (PCV), in monkeys. In: 12th International Symposium on Pneumococci and Pneumococcal Diseases, Toronto, Canada. 2022. p. 585."},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2020-0024"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2020-0023"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040211"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab990"},{"key":"e_1_3_6_46_1","unstructured":"Pfizer. Prevnar 13 summary of product characteristics. 2020. https:\/\/www.medicines.org.uk\/emc\/medicine\/22689#DOCREVISION."},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220453"},{"key":"e_1_3_6_48_1","unstructured":"Public Health England. Pneumococcal disease infections caused by serotypes in Prevenar 13 and not in Prevenar 7. 2021 [accessed 2022 Nov 11]. https:\/\/www.gov.uk\/government\/publications\/pneumococcal-disease-caused-by-strains-in-prevenar-13-and-not-in-prevenar-7-vaccine\/pneumococcal-disease-infections-caused-by-serotypes-in-prevenar-13-and-not-in-prevenar-7."},{"issue":"7","key":"e_1_3_6_49_1","first-page":"107","article-title":"Current situation of invasive pneumococcal disease among children following the introduction of 13-valent pneumococcal conjugate vaccine","volume":"39","author":"National Institute of Infectious Disease","year":"2022","unstructured":"National Institute of Infectious Disease. Current situation of invasive pneumococcal disease among children following the introduction of 13-valent pneumococcal conjugate vaccine. IASR. 2018. 2022;39(7):107\u201328.","journal-title":"IASR"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac376"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17600-6"},{"key":"e_1_3_6_52_1","unstructured":"Epidemiological information on invasive pneumococcal infections in children and adults: overview for 2013-2021 (Japanese). 2021. https:\/\/ipd-information.com\/?page_id=49."},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2019.07.007"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.4103\/jgid.jgid_167_17"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2023.2228162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:43:11Z","timestamp":1770817391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2023.2228162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1080\/21645515.2023.2228162"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2023.2228162","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2228162"}}